Thank you for attending this year's symposium.  Please take a few minutes to provide us your feedback.  

 
1 Start 2 Complete
Please rate the Pancreatic Cancer Symposium 2023 Evaluation on the following:
Strongly AgreeAgreeNeither Agree nor DisagreeDisagreeStrongly Disagree
Overall, the symposium met my expectations
The content of the symposium met my expectations
The virtual format was conducive to the meeting
Please evaluate the content of each of the following sessions
Extremely SatisfiedSatisfiedNeither Satisfied nor DissatisfiedDissatisfiedDid Not Attend
“Controversies in Treatment Sequencing for Operable Pancreatic Cancer” – Douglas B. Evans, MD
“Targeting RAS in Pancreatic Cancer: Opportunities and Challenges” – Andrew Aguirre, MD, PhD
“Precision Oncology for Pancreatic Cancer” – Andrew V. Biankin, AO, MBBS, PhD
“Pancreatic Cancer Surgery in 2023” – Kathleen K. Christians, MD
“Updates from GI ASCO” – Mandana Kamgar, MD, MPH
“Characterizing Pancreatic Cancer EMT Plasticity with Single Cell and Spatial Transcriptomics” – David T. Ting, MD
“Opportunities for Advancing The Management of Pancreatic Neuroendocrine Tumor” – Alexandria T. Phan, MD
“Updates on MR Guided Radiation for Pancreatic Cancer, Current Status and Future Directions” – William A. Hall, MD
With respect to the following: The sessions met my expectations.
Strongly AgreeAgreeNeither Agree nor DisagreeDisagreeStrongly Disagree
Case Discussion
Panel Discussion: How to Incorporate Molecular Profiling into Practice
I would attend another MCW Pancreatic Cancer Symposium
I think that future symposiums should include:
Was the content free of Commercial Bias?
Any additional comments: